Chronic Plaque Psoriasis - Pipeline Review, H2 2015 report provides comprehensive information on the therapeutic development for Chronic Plaque Psoriasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Plaque Psoriasis and special features on late-stage and discontinued projects.
Companies Mentioned in report are AbGenomics International, Inc., Almirall, S.A., Boehringer Ingelheim GmbH, Cellceutix Corporation, Coherus BioSciences, Inc., Eli Lilly and Company, GlaxoSmithKline Plc, Johnson & Johnson, Mitsubishi Tanabe Pharma Corporation, Novartis AG, OPKO Health, Inc., Pfizer Inc., Sandoz International GmbH, Sun Pharma Advanced Research Company Ltd., Takeda Pharmaceutical Company Limited, UCB S.A., XenoPort, Inc.
Get a copy of this report at http://bit.ly/1iwgRbt . This is a premium report price at US$2000 for a single user PDF license
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Chronic Plaque Psoriasis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Chronic Plaque Psoriasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information.